- Home
- CISS vs ZVSA Comparison
CISS vs ZVSA Comparison
Compare CISS & ZVSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CISS
- ZVSA
- Stock Information
- Founded
- CISS 2022
- ZVSA 2014
- Country
- CISS Greece
- ZVSA United States
- Employees
- CISS N/A
- ZVSA N/A
- Industry
- CISS Marine Transportation
- ZVSA Biotechnology: Pharmaceutical Preparations
- Sector
- CISS Consumer Discretionary
- ZVSA Health Care
- Exchange
- CISS Nasdaq
- ZVSA Nasdaq
- Market Cap
- CISS 3.0M
- ZVSA 3.5M
- IPO Year
- CISS N/A
- ZVSA N/A
- Fundamental
- Price
- CISS $0.58
- ZVSA $0.61
- Analyst Decision
- CISS
- ZVSA Strong Buy
- Analyst Count
- CISS 0
- ZVSA 1
- Target Price
- CISS N/A
- ZVSA $240.00
- AVG Volume (30 Days)
- CISS 80.0K
- ZVSA 117.9K
- Earning Date
- CISS 05-27-2025
- ZVSA 05-14-2025
- Dividend Yield
- CISS N/A
- ZVSA N/A
- EPS Growth
- CISS N/A
- ZVSA N/A
- EPS
- CISS N/A
- ZVSA N/A
- Revenue
- CISS $42,296,101.00
- ZVSA N/A
- Revenue This Year
- CISS N/A
- ZVSA N/A
- Revenue Next Year
- CISS N/A
- ZVSA N/A
- P/E Ratio
- CISS N/A
- ZVSA N/A
- Revenue Growth
- CISS 47.17
- ZVSA N/A
- 52 Week Low
- CISS $0.48
- ZVSA $0.58
- 52 Week High
- CISS $13.50
- ZVSA $8.05
- Technical
- Relative Strength Index (RSI)
- CISS 30.12
- ZVSA 30.13
- Support Level
- CISS $0.48
- ZVSA $0.69
- Resistance Level
- CISS $0.74
- ZVSA $0.65
- Average True Range (ATR)
- CISS 0.05
- ZVSA 0.06
- MACD
- CISS 0.00
- ZVSA -0.00
- Stochastic Oscillator
- CISS 37.27
- ZVSA 13.36
About CISS C3is Inc.
C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of our fleet is approximately 64,000 dwt.
About ZVSA ZyVersa Therapeutics Inc.
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.